Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 204

1.

SS18-SSX-regulated miR-17 promotes tumor growth of synovial sarcoma by inhibiting p21WAF1/CIP1.

Minami Y, Kohsaka S, Tsuda M, Yachi K, Hatori N, Tanino M, Kimura T, Nishihara H, Minami A, Iwasaki N, Tanaka S.

Cancer Sci. 2014 Sep;105(9):1152-9. doi: 10.1111/cas.12479. Epub 2014 Sep 3.

2.

SS18-SSX fusion protein-induced Wnt/β-catenin signaling is a therapeutic target in synovial sarcoma.

Trautmann M, Sievers E, Aretz S, Kindler D, Michels S, Friedrichs N, Renner M, Kirfel J, Steiner S, Huss S, Koch A, Penzel R, Larsson O, Kawai A, Tanaka S, Sonobe H, Waha A, Schirmacher P, Mechtersheimer G, Wardelmann E, Büttner R, Hartmann W.

Oncogene. 2014 Oct 16;33(42):5006-16. doi: 10.1038/onc.2013.443. Epub 2013 Oct 28.

PMID:
24166495
3.

MiR-663, a microRNA targeting p21(WAF1/CIP1), promotes the proliferation and tumorigenesis of nasopharyngeal carcinoma.

Yi C, Wang Q, Wang L, Huang Y, Li L, Liu L, Zhou X, Xie G, Kang T, Wang H, Zeng M, Ma J, Zeng Y, Yun JP.

Oncogene. 2012 Oct 11;31(41):4421-33. doi: 10.1038/onc.2011.629. Epub 2012 Jan 16.

PMID:
22249270
4.

Loss of SS18-SSX1 inhibits viability and induces apoptosis in synovial sarcoma.

Carmody Soni EE, Schlottman S, Erkizan HV, Uren A, Toretsky JA.

Clin Orthop Relat Res. 2014 Mar;472(3):874-82. doi: 10.1007/s11999-013-3065-9.

5.

Truncated SSX protein suppresses synovial sarcoma cell proliferation by inhibiting the localization of SS18-SSX fusion protein.

Yoneda Y, Ito S, Kunisada T, Morimoto Y, Kanzaki H, Yoshida A, Shimizu K, Ozaki T, Ouchida M.

PLoS One. 2013 Oct 9;8(10):e77564. doi: 10.1371/journal.pone.0077564. eCollection 2013.

6.

Identification of SHCBP1 as a novel downstream target gene of SS18-SSX1 and its functional analysis in progression of synovial sarcoma.

Peng C, Zhao H, Chen W, Song Y, Wang X, Li J, Qiao Y, Wu D, Ma S, Wang X, Gao C.

Oncotarget. 2016 Oct 11;7(41):66822-66834. doi: 10.18632/oncotarget.11651.

7.
8.

Deflection of vascular endothelial growth factor action by SS18-SSX and composite vascular endothelial growth factor- and chemokine (C-X-C motif) receptor 4-targeted therapy in synovial sarcoma.

Wakamatsu T, Naka N, Sasagawa S, Tanaka T, Takenaka S, Araki N, Ueda T, Nishizawa Y, Yoshikawa H, Itoh K.

Cancer Sci. 2014 Sep;105(9):1124-34. doi: 10.1111/cas.12469. Epub 2014 Sep 3.

9.

Differential roles of SS18-SSX fusion gene and insulin-like growth factor-1 receptor in synovial sarcoma cell growth.

Törnkvist M, Natalishvili N, Xie Y, Girnita A, D'Arcy P, Brodin B, Axelson M, Girnita L.

Biochem Biophys Res Commun. 2008 Apr 11;368(3):793-800. doi: 10.1016/j.bbrc.2008.01.162. Epub 2008 Feb 11.

PMID:
18267106
10.

Induction of p21(WAF1/CIP1) by human synovial sarcoma-associated chimeric oncoprotein SYT-SSX1.

Tsuda M, Watanabe T, Seki T, Kimura T, Sawa H, Minami A, Akagi T, Isobe K, Nagashima K, Tanaka S.

Oncogene. 2005 Dec 1;24(54):7984-90.

PMID:
16103879
11.

Hsa-miR-875-5p exerts tumor suppressor function through down-regulation of EGFR in colorectal carcinoma (CRC).

Zhang T, Cai X, Li Q, Xue P, Chen Z, Dong X, Xue Y.

Oncotarget. 2016 Jul 5;7(27):42225-42240. doi: 10.18632/oncotarget.9944.

12.

Deconstruction of the SS18-SSX fusion oncoprotein complex: insights into disease etiology and therapeutics.

Su L, Sampaio AV, Jones KB, Pacheco M, Goytain A, Lin S, Poulin N, Yi L, Rossi FM, Kast J, Capecchi MR, Underhill TM, Nielsen TO.

Cancer Cell. 2012 Mar 20;21(3):333-47. doi: 10.1016/j.ccr.2012.01.010.

13.

The deoxycholic acid targets miRNA-dependent CAC1 gene expression in multidrug resistance of human colorectal cancer.

Kong Y, Bai PS, Sun H, Nan KJ, Chen NZ, Qi XG.

Int J Biochem Cell Biol. 2012 Dec;44(12):2321-32. doi: 10.1016/j.biocel.2012.08.006. Epub 2012 Aug 10.

PMID:
22903020
14.

SS18-SSX2 and the mitochondrial apoptosis pathway in mouse and human synovial sarcomas.

Jones KB, Su L, Jin H, Lenz C, Randall RL, Underhill TM, Nielsen TO, Sharma S, Capecchi MR.

Oncogene. 2013 May 2;32(18):2365-71, 2375.e1-5. doi: 10.1038/onc.2012.247. Epub 2012 Jul 16.

15.

SYT-SSX is critical for cyclin D1 expression in synovial sarcoma cells: a gain of function of the t(X;18)(p11.2;q11.2) translocation.

Xie Y, Skytting B, Nilsson G, Gasbarri A, Haslam K, Bartolazzi A, Brodin B, Mandahl N, Larsson O.

Cancer Res. 2002 Jul 1;62(13):3861-7.

16.

SRC signaling is crucial in the growth of synovial sarcoma cells.

Michels S, Trautmann M, Sievers E, Kindler D, Huss S, Renner M, Friedrichs N, Kirfel J, Steiner S, Endl E, Wurst P, Heukamp L, Penzel R, Larsson O, Kawai A, Tanaka S, Sonobe H, Schirmacher P, Mechtersheimer G, Wardelmann E, Büttner R, Hartmann W.

Cancer Res. 2013 Apr 15;73(8):2518-28. doi: 10.1158/0008-5472.CAN-12-3023. Epub 2013 Apr 11.

17.

Upregulation of miR-572 transcriptionally suppresses SOCS1 and p21 and contributes to human ovarian cancer progression.

Zhang X, Liu J, Zang D, Wu S, Liu A, Zhu J, Wu G, Li J, Jiang L.

Oncotarget. 2015 Jun 20;6(17):15180-93.

18.

Histone deacetylase inhibitors reverse SS18-SSX-mediated polycomb silencing of the tumor suppressor early growth response 1 in synovial sarcoma.

Lubieniecka JM, de Bruijn DR, Su L, van Dijk AH, Subramanian S, van de Rijn M, Poulin N, van Kessel AG, Nielsen TO.

Cancer Res. 2008 Jun 1;68(11):4303-10. doi: 10.1158/0008-5472.CAN-08-0092.

19.

Downregulation of SS18-SSX1 expression by small interfering RNA inhibits growth and induces apoptosis in human synovial sarcoma cell line HS-SY-II in vitro.

Peng C, Guo W, Yang Y, Zhao H.

Eur J Cancer Prev. 2008 Oct;17(5):392-8. doi: 10.1097/CEJ.0b013e328305a11b.

PMID:
18714179
20.

The synovial-sarcoma-associated SS18-SSX2 fusion protein induces epigenetic gene (de)regulation.

de Bruijn DR, Allander SV, van Dijk AH, Willemse MP, Thijssen J, van Groningen JJ, Meltzer PS, van Kessel AG.

Cancer Res. 2006 Oct 1;66(19):9474-82.

Supplemental Content

Support Center